Drug intelligence / Profile preview

ibuprofen + levomenthol

Development stage
Unknown
Lead developer
Medice
Modality
Small Molecules
Administration
Oral
01

Overview

DoriDuo is a fixed-dose combination lozenge developed by MEDICE Arzneimittel Puetter for the symptomatic treatment of acute pharyngitis (sore throat) in adults. It contains 25 mg of ibuprofen and 1.1 mg of levomenthol. Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) that provides analgesic and anti-inflammatory effects by inhibiting the enzymes cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), thereby reducing the production of pro-inflammatory prostaglandins in the pharyngeal mucosa. Levomenthol acts as an agonist at the TRPM8 (transient receptor potential melastatin 8) cold receptors, producing a cooling sensation and providing mild local anesthetic properties to soothe irritation. This combination is intended for short-term use to manage pain and swelling associated with throat infections, offering both systemic anti-inflammatory action and local sensory relief.

Brand names
DoriDuo
Other names
Ibuprofen/Levomenthol
02

Targets

TRPM8 (Transient receptor potential cation channel subfamily M member 8)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on ibuprofen + levomenthol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ibuprofen + levomenthol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call